MET and neoplasm: A prognostic biomarker (HER2; BRAF V600E mu­tations; RET gene rearrangements; high-level MET amplification) is indicative of patient survival independent of the treatment received because the biomarker is an indicator of the innate tumor aggressiveness [23].